Reishi-MRL

Reishi-MRL

reishi
reishi

Cultivation Process of Reishi-MRL

Mycology Research Laboratories Ltd.´s Ganoderma lucidum, is grown on a sterilised (autoclaved) substrate under ISO 22000:2018 standards in the EU.

This cultivation process ensures the powder complies with the EU regulation 1881/2006 for contamination of pesticides and heavy metals. The cultivation system is proprietary, allowing for standardised production of Ganoderma lucidum.

MRL mushrooms biomass offers a mixture of many co-operating and co-related healthful bioavailable ingredients prepared by nature itself – it is thus a truly pure natural product.

After cultivation the Ganoderma lucidum is then manufactured in the Netherlands into 500 mg tablets and in various powder forms to FSSC 22000 (Version 4.1) standards.

Veterinary products are manufactured under veterinary registration number (NL217476).

Moreover, all powder presentations are produced and manufactured in accordance with both EU and UK organic standards.

EU PT Bio 05 Logo
EU NL Bio 01 Logo
EU PT Bio 05 Logo
EU pt Bio 01 Logo
EU PT Bio 05 Logo
APCER 22000 IQNet Logos
UK Organic Logo
UK Organic Logo

Chemical and Biological Properties *

Each Tablet of Reishi-MRL contains

Ganoderma lucidum - biomass powder 500 mg

Other ingredients

Microcrystalline Cellulose
Silica
Vegetable Magnesium Sterate

Reishi-MRL - Enzyme Activity Per 750 mg Tablet

Protein content 22.2 mg
Reducing sugars 24.0 mg
Protein-bound polysaccharide 69.5 mg
Glucose 2-oxidase activity 8.2 mU
Peroxidase activity 11.2 mU
Laccase activity 451.5 mU
Glucoamylase / beta-glucansase activity 2.7 U
Protease activity 4.4 mU
Superoxide dismutase (SOD) activity 50.4 mU
Cytochrome P-450 0.66 nmoles
Cytochrome P-450 reductase 7.05 mU
Secondary metabolites (Thrombin inhibitors) 4.4%